Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Amicus Therapeutics (FOLD) Invested Capital (2016 - 2025)

Amicus Therapeutics filings provide 16 years of Invested Capital readings, the most recent being $666.9 million for Q4 2025.

  • On a quarterly basis, Invested Capital rose 14.16% to $666.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $666.9 million, a 14.16% increase, with the full-year FY2025 number at $666.9 million, up 14.16% from a year prior.
  • Invested Capital hit $666.9 million in Q4 2025 for Amicus Therapeutics, up from $622.4 million in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $765.3 million in Q3 2021 to a low of $495.2 million in Q1 2023.
  • Median Invested Capital over the past 5 years was $576.2 million (2024), compared with a mean of $583.8 million.
  • Biggest five-year swings in Invested Capital: rose 18.78% in 2021 and later plummeted 31.55% in 2022.
  • Amicus Therapeutics' Invested Capital stood at $696.7 million in 2021, then dropped by 26.08% to $515.0 million in 2022, then rose by 6.41% to $548.0 million in 2023, then grew by 6.59% to $584.2 million in 2024, then increased by 14.16% to $666.9 million in 2025.
  • The last three reported values for Invested Capital were $666.9 million (Q4 2025), $622.4 million (Q3 2025), and $595.6 million (Q2 2025) per Business Quant data.